Toxicities associated with bleomycin

Journal of the Royal College of Physicians of Edinburgh

Volumn 40, Issue 3, 2010, Pages 213-215

  Fyfe, A J ^b   McKay, P ^a  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^b NONE

Author keywords

ABVD chemotherapy; Bleomycin; Flagellate erythema; Hodgkin lymphoma; Pneumonitis

Indexed keywords

ANTIBIOTIC AGENT; BETAMETHASONE VALERATE; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; PREDNISOLONE; VINBLASTINE;

ADULT; ALOPECIA; ARTICLE; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DRUG ERUPTION; DRUG WITHDRAWAL; DYSPNEA; ECZEMA; ERYTHEMA; FEMALE; FLAGELLATE ERYTHEMA; HODGKIN DISEASE; HUMAN; LUNG FIBROSIS; LUNG INFECTION; LUNG TOXICITY; MALE; MULTIPLE CYCLE TREATMENT; NAIL BED; PATIENT REFERRAL; PNEUMONIA; RAYNAUD PHENOMENON; SCLERODERMA; SIDE EFFECT; SKIN TOXICITY; SKIN ULCER; STOMATITIS; THORAX RADIOGRAPHY;

ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; DRUG ERUPTIONS; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA;

EID: 77957372367     PISSN: 14782715     EISSN: None     Source Type: Journal    
DOI: 10.4997/JRCPE.2010.306     Document Type: Article

References (15)

1. Chen J, Stubbe J. Bleomycins: towards better therapeutics. Nat Rev Cancer 2005; 5: 102-12. doi: 10.1038/nrc1547
2. Sleijfer S. Bleomycin-induced pneumonitis. Chest 2001; 120: 617-24. doi: 10.1378/chest.120.2.617
3. Mowad CM, Nguyen TV, Elenitsas R et al. Bleomycin-induced flagellate dermatitis: a clinical and histopathological review. Br J Derm 1994; 131: 700-2. doi: 10.1111/j.1365-2133.1994.tb04986.x
4. Moulin G, Fiere B, Beyvin A. [Cutaneous pigmentation caused by bleomycin.] Bull Soc Fr Dermatol Syphiligr 1970; 77: 293-6. In French.
5. Chen Y-B, Rahemtullah A, Breeden E et al. Bleomycin-induced flagellate erythema. J Clin Oncol 2007; 25: 898-900. doi: 10.1200/JCO.2006.09.7691
6. Todkill D, Taibjee S, Borg A et al. Flagellate erythema due to bleomycin. Br J Haematol 2008; 142: 857. doi: 10.1111/j.1365-2141.2008.07238.x
7. Duhra P, Ilchyshyn A, Das RN. Bleomycin-induced flagellate erythema. Clin Exp Dermatol 1991; 16: 216-7. doi: 10.1111/j.1365-2230.1991. tb00352.x
8. Yamamoto T. Bleomycin and the skin. Br J Dermatol 2006; 155: 869-75. doi: 10.1111/j.1365-2133.2006.07474.x
9. White DA, Stover DE. Severe bleomycin-induced pneumonitis: clinical features and response to corticosteroids. Chest 1984; 86: 723-8. doi: 10.1378/chest.86.5.723
10. Martin WG, Ristow KM, Habermann TM et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin lymphoma. J Clin Oncol 2005; 23: 7614-20. doi: 10.1200/JCO.2005.02.7243
11. Saxman SB, Nichols CR, Einhorn LH. Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor. Chest 1997; 111: 657-60. doi: 10.1378/chest.111.3.657
12. Evens AM, Cilley J, Ortiz T et al. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin's lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol 2007; 137: 545-52. doi: 10.1111/j.1365-2141.2007.06598.x
13. Stewart R, Allan J, Drummond M et al. Audit of ABVD chemotherapy for Hodgkin lymphoma patients regardless of absolute neutrophil count and without G-CSF, no treatment delays and optimal dose intensity. Haematologica 2009; 94(Suppl 2): 635.
14. Danson S, Blackhall F, Hulse P et al. Interstitial lung disease in lung cancer: separating disease progression from treatment effects. Drug Saf 2005; 28: 103-13. doi: 10.2165/00002018-200528020-00002
15. Canellos GP, Duggan D, Johnson J et al. How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen? J Clin Oncol 2004; 22: 1532-3. doi: 10.1200/JCO.2004.99.010